Article

Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer

2023-03-22

Abstract excerpt

<title>Abstract</title> <p>The optimal treatment for patients with oligometastatic non-small cell lung cancer (NSCLC) remains unclear. Some patients with oligometastatic disease can experience prolonged remission after locally consolidative radiation therapy (RT), while others harbor micrometastatic disease (below current limits of detection by imaging) that may benefit from further prioritization of systemic the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 50e7b249-0ece-52fb-b32b-f7ae9e6e96f4
DOI: 10.21203/rs.3.rs-2688927/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancerDOI 10.21203/rs.3.rs-2688927/v1Read

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung CancerSemantic proximity Read

Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung CancerSemantic proximity Read

Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial.Semantic proximity Read

Clinical utility of analyzing circulating tumor DNA in patients with non-small cell lung carcinomaSemantic proximity Read

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.Semantic proximity Read

Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer.Semantic proximity Read

Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers.Semantic proximity Read

Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation.Semantic proximity Read

ctDNA detection by personalised assays in early-stage NSCLCSemantic proximity Read

The promises and perils of circulating tumor DNA for monitoring immunotherapy response in non-small cell lung cancerSemantic proximity Read

Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patientsSemantic proximity Read

Assessing In House Comprehensive Genomic Profiling by Liquid Biopsy for NSCLC PatientsSemantic proximity Read